Alnylam Pharmaceuticals, Inc. (ALNY)
After hours:
| Previous close | 229.39 |
| Open | 229.39 |
| Bid | 225.05 x 1200 |
| Ask | 243.45 x 1000 |
| Day's range | 228.34 - 236.80 |
| 52-week range | 117.58 - 236.80 |
| Volume | |
| Avg. volume | 990,466 |
| Market cap | 28.068B |
| Beta (5Y monthly) | 0.74 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.49 |
| Earnings date | 26 Oct 2022 - 31 Oct 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 228.45 |
- Motley Fool
Is This Unknown Growth Stock a Buy After Its Blast Off?
Alnylam Pharmaceuticals' (NASDAQ: ALNY) stock went vertical in the past month -- up over 50% -- and there might be even more growth on the way. Sales of its top-earning medicines are booming, and breakthroughs in clinical trials have added to the enthusiasm. Alnylam has a small handful of medicines on the market, led by its drugs Onpattro and Amvuttra, which are intended to treat peripheral neuropathy caused by hereditary transthyretin amyloidosis (ATTR), which is a rare but deadly and progressively worsening heart disease.
- Motley Fool
Why Alnylam Pharmaceuticals Stock Is Vaulting Higher Today
Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) are poised to post a new all-time high upon market open Wednesday. The RNA interference (RNAi) drug specialist's stock price rose by as much as 53% in premarket action this morning. Ahead of the opening bell, Alnylam announced that its closely watched phase 3 Apollo-B study of the RNAi therapy, patisiran, in patients with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy met its primary endpoint of change in baseline in the 6-minute walk test at 12 months compared to placebo.
- Business Wire
Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass., August 03, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy, met the primary endpoint of change from baseline in the 6-Minute Walk Test (6-MWT) at 12 months compared to placebo (p-value 0.0162). The study also met the first secondary endpoint o
